NewcelX (NCEL) Non-Current Deffered Revenue (2019 - 2024)
NewcelX (NCEL) posted quarterly Non-Current Deffered Revenue of $2.5 million for Q4 2024, little changed year-over-year from $2.5 million in Q1 2024, and little changed quarter-over-quarter from $2.5 million in Q2 2024.
NewcelX (NCEL) Non-Current Deffered Revenue (2019 - 2024) Analysis & Trends
NewcelX (NCEL) has reported Non-Current Deffered Revenue for 6 consecutive years, with $2.5 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million; the TTM figure through Dec 2024 stood at $2.5 million (changed 0.0% YoY), while the FY2024 annual figure was $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was little changed at $2.5 million in Q4 2024 per NCEL's latest filing, from $2.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.5 million in Q2 2024 and bottomed at $2.5 million in Q4 2020.
- Historically, Non-Current Deffered Revenue has averaged $2.5 million across 5 years, with a median of $2.5 million in 2020.
- Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue changed 0.0% — and 2024, when it climbed 0.0%.
- NewcelX's Non-Current Deffered Revenue stood at $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then increased by 0.0% to $2.5 million in 2024.
- Business Quant data shows NCEL's Non-Current Deffered Revenue at $2.5 million in Q4 2024, $2.5 million in Q2 2024, and $2.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Dec 31, 2019 | 2.50 Mn |